Literature DB >> 24649116

Eradication of therapy-resistant cancer cells in gastrointestinal organs.

Shimpei Nishikawa1, Masamitsu Konno2, Atsushi Hamabe1, Shinichiro Hasegawa1, Hisataka Ogawa1, Yoshihiro Kano1, Takahito Fukusumi3, Katsuya Ohta1, Yuko Noguchi2, Miyuki Ozaki1, Toshihiro Kudo2, Daisuke Sakai2, Naotsugu Haraguchi2, Taroh Satoh2, Yuichiro Doki4, Masaki Mori4, Hideshi Ishii2.   

Abstract

Early stages of cancer are curable by surgical removal of the primary lesions, however, more advanced cases are often refractory to therapeutic approaches and are more commonly life-threatening, primarily due to cancer metastasis in gastrointestinal cancers. Such biological events are collectively characterized as tumor heterogeneity, the cause of which is the existence of cancer stem cells. To improve cancer survival, therapy-resistant cancer cells should be eradicated. To this end, recent rapid progress in medical science, such as innovative medical technologies including cancer reprogramming, RNA pharmacology and drug delivery systems, all of which effectively target cancer stem cells, has facilitated this objective.

Entities:  

Keywords:  cancer stem cell; cancer therapy; gastrointestinal organs

Year:  2012        PMID: 24649116      PMCID: PMC3956226          DOI: 10.3892/mco.2012.13

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  33 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Hypoxia enhances the generation of induced pluripotent stem cells.

Authors:  Yoshinori Yoshida; Kazutoshi Takahashi; Keisuke Okita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Cell Stem Cell       Date:  2009-08-27       Impact factor: 24.633

3.  The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network.

Authors:  M Fareh; L Turchi; V Virolle; D Debruyne; F Almairac; S de-la-Forest Divonne; P Paquis; O Preynat-Seauve; K-H Krause; H Chneiweiss; T Virolle
Journal:  Cell Death Differ       Date:  2011-07-01       Impact factor: 15.828

4.  Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.

Authors:  Hyenjong Hong; Kazutoshi Takahashi; Tomoko Ichisaka; Takashi Aoi; Osami Kanagawa; Masato Nakagawa; Keisuke Okita; Shinya Yamanaka
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

5.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

Authors:  Catherine A O'Brien; Aaron Pollett; Steven Gallinger; John E Dick
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

6.  Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency.

Authors:  Frederick Anokye-Danso; Chinmay M Trivedi; Denise Juhr; Mudit Gupta; Zheng Cui; Ying Tian; Yuzhen Zhang; Wenli Yang; Peter J Gruber; Jonathan A Epstein; Edward E Morrisey
Journal:  Cell Stem Cell       Date:  2011-04-08       Impact factor: 24.633

7.  MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways.

Authors:  Shi-Lung Lin; Donald C Chang; Shao-Yao Ying; Davey Leu; David T S Wu
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

8.  Characterization of a side population of cancer cells from human gastrointestinal system.

Authors:  Naotsugu Haraguchi; Tohru Utsunomiya; Hiroshi Inoue; Fumiaki Tanaka; Koshi Mimori; Graham F Barnard; Masaki Mori
Journal:  Stem Cells       Date:  2005-10-20       Impact factor: 6.277

9.  Tumor heterogeneity and drug resistance.

Authors:  D L Dexter; J T Leith
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

Review 10.  Is tumor growth sustained by rare cancer stem cells or dominant clones?

Authors:  Jerry M Adams; Andreas Strasser
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.